Olena Sivak

1.4k total citations
44 papers, 1.0k citations indexed

About

Olena Sivak is a scholar working on Molecular Biology, Infectious Diseases and Oncology. According to data from OpenAlex, Olena Sivak has authored 44 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 9 papers in Infectious Diseases and 9 papers in Oncology. Recurrent topics in Olena Sivak's work include Antifungal resistance and susceptibility (9 papers), Research on Leishmaniasis Studies (5 papers) and Drug Transport and Resistance Mechanisms (5 papers). Olena Sivak is often cited by papers focused on Antifungal resistance and susceptibility (9 papers), Research on Leishmaniasis Studies (5 papers) and Drug Transport and Resistance Mechanisms (5 papers). Olena Sivak collaborates with scholars based in Canada, United States and United Kingdom. Olena Sivak's co-authors include Kishor M. Wasan, Pavel Gershkovich, Carlos León, Ellen K. Wasan, Rita Tory, Karen H. Bartlett, Kevin Gregory‐Evans, Cheryl Y. Gregory‐Evans, Verica Risovic and Jonathan C.M. Wong and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Olena Sivak

44 papers receiving 988 citations

Peers

Countries citing papers authored by Olena Sivak

Since Specialization

Citations

This map shows the geographic impact of Olena Sivak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Olena Sivak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Olena Sivak more than expected).

Fields of papers citing papers by Olena Sivak

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Olena Sivak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Olena Sivak. The network helps show where Olena Sivak may publish in the future.

Co-authorship network of co-authors of Olena Sivak

This figure shows the co-authorship network connecting the top 25 collaborators of Olena Sivak. A scholar is included among the top collaborators of Olena Sivak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Olena Sivak. Olena Sivak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Targeting adenocarcinoma and enzalutamide‑resistant prostate cancer using the novel anti‑androgen inhibitor ADA‑308 2024 ·Oncology Reports ·(unknown), Fraser Johnson, Sahil Kumar, Olena Sivak, (unknown), Milla Koistinaho, Anu Muona, Amina Zoubeidi	1
2	MP20-07 NPTX1 IS A NOVEL SERUM BIOMARKER INDUCED BY ARPI TREATED PROSTATE CANCER AND ENRICHED IN LINEAGE PLASTICITY WITH BRN2 HIGH 2023 ·The Journal of Urology ·Takeshi Namekawa, Joshua Scurll, Maxim Kobelev, Dwaipayan Ganguli, Olena Sivak, Martin Gleave, (unknown), Canadá, Eva Corey, Colm Morrissey, Amina Zoubeidi	1
3	Efficacy of Postnatal In Vivo Nonsense Suppression Therapy in a Pax6 Mouse Model of Aniridia 2017 ·Molecular Therapy — Nucleic Acids ·Xia Wang, Kevin Gregory‐Evans, Kishor M. Wasan, Olena Sivak, Xianghong Shan, Cheryl Y. Gregory‐Evans	46
4	NLRP3 inflammasome activation drives bystander cone photoreceptor cell death in a P23H rhodopsin model of retinal degeneration 2016 ·Human Molecular Genetics ·(unknown), Andrew Metcalfe, (unknown), Olena Sivak, Anat Yanai, (unknown), Orson L. Moritz, Cheryl Y. Gregory‐Evans, Kevin Gregory‐Evans	71
5	Novel oral amphotericin B formulation (iCo-010) remains highly effective against murine systemic candidiasis following exposure to tropical temperature 2014 ·Drug Development and Industrial Pharmacy ·Kishor M. Wasan, Olena Sivak, Karen H. Bartlett, Ellen K. Wasan, Pavel Gershkovich	10
6	A simple and sensitive method for determination of vitamins D₃and K₁in rat plasma: application for anin vivopharmacokinetic study 2013 ·Drug Development and Industrial Pharmacy ·Pavel Gershkovich, (unknown), Olena Sivak, (unknown), Kishor M. Wasan	14
7	Impact of co-administration of protonated nanostructured aluminum silicate (cholesterol absorption inhibitor) on the absorption of lipid soluble vitamins D3 and K1: An assessment of pharmacokinetic and in vitro intraluminal processing 2013 ·European Journal of Pharmaceutical Sciences ·(unknown), Olena Sivak, (unknown), (unknown), Ankur Midha, Jacob A. Gordon, (unknown), Kishor M. Wasan	3
8	Efficacy and toxicity of a tropically stable lipid-based formulation of amphotericin B (iCo-010) in a rat model of invasive candidiasis 2012 ·International Journal of Pharmaceutics ·(unknown), Pavel Gershkovich, Olena Sivak, Ellen K. Wasan, Karen H. Bartlett, Kishor M. Wasan	9
9	Tropically stable novel oral lipid formulation of amphotericin B (iCo-010): biodistribution and toxicity in a mouse model 2011 ·Lipids in Health and Disease ·Olena Sivak, Pavel Gershkovich, Molly Lin, Ellen K. Wasan, Jinying Zhao, David Owen, John G. Clement, Kishor M. Wasan	26
10	Assessment of Cholesterol Absorption Inhibitors Nanostructured Aluminosilicate and Cholestyramine Using In Vitro Lipolysis Model 2011 ·Journal of Pharmaceutical Sciences ·Pavel Gershkovich, Olena Sivak, (unknown), (unknown), Kishor M. Wasan	14
11	Long-circulating non-toxic blood pool imaging agent based on hyperbranched polyglycerols 2011 ·International Journal of Pharmaceutics ·Katayoun Saatchi, (unknown), Pavel Gershkovich, Olena Sivak, Kishor M. Wasan, Rajesh K. Kainthan, Donald E. Brooks, Urs O. Häfeli	36
12	Protonated nanostructured aluminosilicate (NSAS) reduces plasma cholesterol concentrations and atherosclerotic lesions in Apolipoprotein E deficient mice fed a high cholesterol and high fat diet 2009 ·Lipids in Health and Disease ·Olena Sivak, (unknown), Pavel Gershkovich, Panayiotis P. Constantinides, Kishor M. Wasan	13
13	Visceral leishmaniasis affects liver and spleen concentrations of amphotericin B following administration to mice 2009 ·Journal of Antimicrobial Chemotherapy ·Pavel Gershkovich, Ellen K. Wasan, Olena Sivak, R. Li, Xiaotong Zhu, Karl A. Werbovetz, Richard R. Tidwell, John G. Clement, Sheila J. Thornton, Kishor M. Wasan	20
14	Inhibition of intestinal absorption of cholesterol by surface-modified nanostructured aluminosilicate compounds 2008 ·Journal of Pharmaceutical Sciences ·Pavel Gershkovich, (unknown), Olena Sivak, Panayiotis P. Constantinides, Kishor M. Wasan	24
15	Assessing the antifungal activity, pharmacokinetics, and tissue distribution of amphotericin B following the administration of Abelcet® and AmBisome® in combination with caspofungin to rats infected with Aspergillus fumigatus 2006 ·Journal of Pharmaceutical Sciences ·Kishor M. Wasan, Olena Sivak, (unknown), Verica Risovic, Karen H. Bartlett	16
16	Determining the Critical Micelle Concentration of a Novel Lipid‐Lowering Agent, Disodium Ascorbyl Phytostanyl Phosphate (FM‐VP4), Using a Fluorescence Depolarization Procedure 2004 ·Drug Development and Industrial Pharmacy ·Kishor M. Wasan, Eugene Choo, Olena Sivak, Simon Wallis, Kevin Letchford, Helen M. Burt, David J. Stewart, (unknown)	7
17	Unidirectional Inhibition of Lipid Transfer Protein I-Mediated Transfer of Cholesteryl Esters Between High-Density and Low-Density Lipoproteins by Amphotericin B Lipid Complex 2004 ·Pharmaceutical Research ·Olena Sivak, (unknown), (unknown), Kishor M. Wasan	5
18	Assessing the antifungal activity and toxicity profile of amphotericin B lipid complex (ABLC; Abelcet®) in combination with caspofungin in experimental systemic aspergillosis 2004 ·Journal of Pharmaceutical Sciences ·Olena Sivak, Karen H. Bartlett, Verica Risovic, Eugene Choo, Fawziah Marra, (unknown), Kishor M. Wasan	25
19	Plasma protein binding, lipoprotein distribution and uptake of free and lipid-associated BCL-2 antisense oligodeoxynucleotides (G3139) in human melanoma cells 2002 ·International Journal of Pharmaceutics ·Ellen K. Wasan, Dawn Waterhouse, Olena Sivak, Marcel B. Bally, Richard Klasa, Kishor M. Wasan	9
20	Cyclosporine A transfer between high‐ and low‐density lipoproteins: Independent from lipid transfer protein I‐facilitated transfer of lipoprotein‐coated phospholipids because of high affinity of cyclosporine a for the protein component of lipoproteins 2001 ·Journal of Pharmaceutical Sciences ·(unknown), Olena Sivak, (unknown), Kishor M. Wasan	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact